CHINA SXT PHARMACEUTICALS IN (SXTC) Forecast, Price Target & Analyst Ratings
NASDAQ:SXTC • VGG2161P1650
2.13 USD
+0.09 (+4.41%)
At close: Mar 9, 2026
2.15 USD
+0.02 (+0.94%)
After Hours: 3/9/2026, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CHINA SXT PHARMACEUTICALS IN (SXTC).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateN/A
ChartMill Buy Consensus
0.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $2.13 to mean target of N/A, Based on 0 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
0.00%
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | ||
|---|---|---|---|---|
| Revenue YoY % growth | 1.97M -24.23% | 1.929M -2.11% | 1.741M -9.73% | |
| EBITDA YoY % growth | -5.01M -2.87% | -1.889M 62.29% | -1.592M 15.72% | |
| EBIT YoY % growth | -5.26M -1.35% | -2.092M 60.22% | -1.674M 19.97% | |
| Operating Margin | -267.01% | -108.49% | -96.18% | |
| EPS YoY % growth | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A